| Original study . | Geographic location . | Sample type . | Cohort size . | ● Type I IFN signature shown in original study . | o Type I IFN signature reported in subsequent analysis . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Active disease . | Correlated radiographical disease . | Treatment response . | Joosten et al., 2013 . | Blankley et al., 2016 . | Sambarey et al., 2017a . | Singhania et al., 2017 . | ||||
| Jacobsen et al., 2007 | Germany | PBMCs | Active TB (n = 9); LTBI (n = 9) | o | ||||||
| Mistry et al., 2007 | South Africa | Whole blood | Active, recurrent, or cured TB; LTBI (n = 10/group) | o | ||||||
| Berry et al., 2010 a | UK | Whole blood (and sorted cells) | Active TB (n = 21); LTBI (n = 21); HCs (n = 12) | ● | ● | ● | o | o | o | o |
| South Africa | Whole blood | Active TB (n = 20); LTBI (n = 31) | ● | o | o | o | o | |||
| Maertzdorf et al., 2011a | South Africa | Whole blood | Active TB (n = 46); LTBI (n = 25); HC (n = 37) | ● | o | o | ||||
| Maertzdorf et al., 2011b | The Gambia | Whole blood | Active TB (n = 33); LTBI (n = 34); HC (n = 9) | ● | o | |||||
| Bloom et al., 2012 | South Africa | Whole blood | active TB (n = 33); LTBI (n = 34); HC (n = 9) | ● | ● | o | o | |||
| Maertzdorf et al., 2012 | Germany | Whole blood | Active TB (n = 8); LTBI (n = 4); HC (n = 14) | ● | o | o | ||||
| Ottenhoff et al., 2012 | Indonesia | PBMCs | Active TB over time during treatment (n = 23); HC (n = 23) | ● | ● | o | o | |||
| Cliff et al., 2013 | South Africa | Whole blood | Active TB over time during treatment (n = 27) | ● | ● | o | o | o | ||
| Bloom et al., 2013 | UK | Whole blood (and sorted cells) | Active TB (n = 35); HCs (n = 113) | ● | o | o | o | |||
| Kaforou et al., 2013 | South Africa, Malawi | Whole blood | Active TB (HIV−/+; n = 195); LTBI (HIV−/+; n = 167) | o | o | |||||
| Cai et al., 2014 | China | PBMCs | active TB (n = 9); LTBI (n = 6); HC (n = 6) | o | ||||||
| Anderson et al., 2014 | Kenya | Whole blood | Active TB (n = 79); LTBI (n = 14) | o | ||||||
| South Africa, Malawi | Active TB (n = 110); LTBI (n = 54) | o | ||||||||
| Roe et al., 2016 | UK | Whole blood | Active TB (n = 46); postrecovery (n = 31) | ● | ● | |||||
| Zak et al., 2016 | South Africa | Whole blood | Progressors (n = 40); nonprogressors (n = 104) | ● | o | |||||
| Sambarey et al., 2017b | India | Whole blood | Active TB (n = 19); LTBI (n = 13); HCs (n = 15) | ● | ||||||
| Singhania et al., 2017 | UK | Whole blood | Active TB (n = 53); LTBI (n = 49); HCs (n = 50) | ● | ||||||
| Esmail et al., 2018 | South Africa | Whole blood | Active TB (n = 15); subclinical TB (n = 10); latent TB (n = 25) | ● | ||||||
| Original study . | Geographic location . | Sample type . | Cohort size . | ● Type I IFN signature shown in original study . | o Type I IFN signature reported in subsequent analysis . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Active disease . | Correlated radiographical disease . | Treatment response . | Joosten et al., 2013 . | Blankley et al., 2016 . | Sambarey et al., 2017a . | Singhania et al., 2017 . | ||||
| Jacobsen et al., 2007 | Germany | PBMCs | Active TB (n = 9); LTBI (n = 9) | o | ||||||
| Mistry et al., 2007 | South Africa | Whole blood | Active, recurrent, or cured TB; LTBI (n = 10/group) | o | ||||||
| Berry et al., 2010 a | UK | Whole blood (and sorted cells) | Active TB (n = 21); LTBI (n = 21); HCs (n = 12) | ● | ● | ● | o | o | o | o |
| South Africa | Whole blood | Active TB (n = 20); LTBI (n = 31) | ● | o | o | o | o | |||
| Maertzdorf et al., 2011a | South Africa | Whole blood | Active TB (n = 46); LTBI (n = 25); HC (n = 37) | ● | o | o | ||||
| Maertzdorf et al., 2011b | The Gambia | Whole blood | Active TB (n = 33); LTBI (n = 34); HC (n = 9) | ● | o | |||||
| Bloom et al., 2012 | South Africa | Whole blood | active TB (n = 33); LTBI (n = 34); HC (n = 9) | ● | ● | o | o | |||
| Maertzdorf et al., 2012 | Germany | Whole blood | Active TB (n = 8); LTBI (n = 4); HC (n = 14) | ● | o | o | ||||
| Ottenhoff et al., 2012 | Indonesia | PBMCs | Active TB over time during treatment (n = 23); HC (n = 23) | ● | ● | o | o | |||
| Cliff et al., 2013 | South Africa | Whole blood | Active TB over time during treatment (n = 27) | ● | ● | o | o | o | ||
| Bloom et al., 2013 | UK | Whole blood (and sorted cells) | Active TB (n = 35); HCs (n = 113) | ● | o | o | o | |||
| Kaforou et al., 2013 | South Africa, Malawi | Whole blood | Active TB (HIV−/+; n = 195); LTBI (HIV−/+; n = 167) | o | o | |||||
| Cai et al., 2014 | China | PBMCs | active TB (n = 9); LTBI (n = 6); HC (n = 6) | o | ||||||
| Anderson et al., 2014 | Kenya | Whole blood | Active TB (n = 79); LTBI (n = 14) | o | ||||||
| South Africa, Malawi | Active TB (n = 110); LTBI (n = 54) | o | ||||||||
| Roe et al., 2016 | UK | Whole blood | Active TB (n = 46); postrecovery (n = 31) | ● | ● | |||||
| Zak et al., 2016 | South Africa | Whole blood | Progressors (n = 40); nonprogressors (n = 104) | ● | o | |||||
| Sambarey et al., 2017b | India | Whole blood | Active TB (n = 19); LTBI (n = 13); HCs (n = 15) | ● | ||||||
| Singhania et al., 2017 | UK | Whole blood | Active TB (n = 53); LTBI (n = 49); HCs (n = 50) | ● | ||||||
| Esmail et al., 2018 | South Africa | Whole blood | Active TB (n = 15); subclinical TB (n = 10); latent TB (n = 25) | ● | ||||||
Type I IFN signature reported in original study (●) and/or in subsequent analysis by others (o). HC, healthy control; LTBI, latent tuberculosis infection; PBMC, peripheral blood mononuclear cell; TB, tuberculosis.
Original study providing the first data in human disease to support a role for type I IFN in the pathogenesis of tuberculosis.